Jiangsu Hengrui Pharmaceuticals (01276): SHR-3045 injection approved to conduct clinical trials.
Hengrui Medicine (01276) announced that its subsidiaries, Guangdong Hengrui Medicine Co., Ltd. and Shanghai Hengrui Medicine Co., Ltd...
Jiangsu Hengrui Pharmaceuticals (01276) announced that its subsidiaries, Guangdong Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd., have received approval from the National Medical Products Administration (NMPA) for a clinical trial of SHR-3045 injection. The clinical trial is expected to start soon.
SHR-3045 injection is a biopharmaceutical product developed independently by the company, which is expected to suppress the function of immune cells in the treatment of rheumatoid arthritis, thereby inhibiting inflammation and improving clinical symptoms. As of now, there are no similar drugs approved for market both domestically and internationally. The cumulative research and development investment in the SHR-3045 injection project is approximately 35.54 million yuan.
Related Articles
TIME WATCH (02033) issued a profit warning, anticipating an annual loss of HK$17 million for the company's shareholders compared to a profit.
Yu Cheng Kejin (00279) completes the placement of approximately 191 million shares.
Novo Nordisk A/S Sponsored ADR Class B (NVO.US) jumped in pre-market trading, Ozempic has better cardiovascular protective effects than traditional drugs like Lantus.
TIME WATCH (02033) issued a profit warning, anticipating an annual loss of HK$17 million for the company's shareholders compared to a profit.
Yu Cheng Kejin (00279) completes the placement of approximately 191 million shares.
Novo Nordisk A/S Sponsored ADR Class B (NVO.US) jumped in pre-market trading, Ozempic has better cardiovascular protective effects than traditional drugs like Lantus.
